+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are evaluating elritercept compared with epoetin alfa to treat anemia in adults with lower-risk myelodysplastic syndromes LR-MDS who require regular red blood cell transfusions. The study focuses on how well elritercept reduces the need for transfusions, improves hemoglobin blood levels, and affects tiredness and quality of life. It also monitors the safety of elritercept and its impact on the disease in bone marrow and other body areas. Participants will be randomly assigned to receive either elritercept or epoetin alfa. Elritercept is given as a subcutaneous injection starting at 3.75 mgkg once every 4 weeks, with possible dose increases to 5.0 mgkg if needed. Epoetin alfa is given as a subcutaneous injection starting at 450 IUkg once weekly, with potential dose escalation up to 1050 IUkg maximum 80,000 IU. Treatment cycles last 28 days, and dosing continues throughout the study. During the study, participants will have regular assessments including blood tests to measure hemoglobin levels and transfusion requirements. Researchers will track fatigue and quality of life using specific questionnaires. Safety will be closely monitored, including side effects and changes in disease status. The main outcome is the proportion of participants who become independent of red blood cell transfusions for at least 12 consecutive weeks while having improved hemoglobin. The study may last up to approximately 5 years from the first dose to end of treatment.

Age: 18Years +All GendersPhase 3
162 locations
P

Actively Recruiting

Researchers are conducting a phase 3 clinical trial comparing two treatment combinations for adults with ER-positive, HER2-negative advanced breast cancer who have not received prior systemic anti-cancer treatment for this condition. The study aims to evaluate the effectiveness and safety of palazestrant combined with ribociclib versus letrozole combined with ribociclib. Participants include men and women with locally advanced or metastatic breast cancer not suitable for curative therapy. Participants are randomly assigned to one of two groups. One group receives palazestrant 90 mg once daily, ribociclib 600 mg once daily on days 1-21 of a 28-day cycle, and a placebo matching letrozole daily. The other group receives letrozole 2.5 mg once daily, ribociclib 600 mg once daily on days 1-21 of a 28-day cycle, and a placebo matching palazestrant daily. Treatment cycles repeat every 28 days, and the study includes approximately 1,000 participants worldwide. During the study, participants will be monitored for disease progression and overall survival, with primary measurements taken from the date of randomization until disease progression or death, estimated up to 3.5 years. Safety, drug levels, and patient-reported health outcomes will be assessed regularly. The trial includes long-term follow-up for up to 5.5 years to evaluate overall survival. Participants will have scheduled visits for assessments and monitoring throughout their involvement in the trial.

Age: 18Years +All GendersPhase 3
200 locations
I

Actively Recruiting

Researchers are investigating the best way to start peritoneal dialysis PD for patients with kidney failure, a condition that is fatal without dialysis. This international, multicenter trial compares the usual full dose PD, given continuously 247, with a lower starting dose that increases over time. The study aims to see if starting with less intensive PD can preserve quality of life, reduce treatment burden, be safe, more cost-effective, and better for the environment. Participants are randomized to one of two groups incremental PD, which starts with fewer exchanges per week and increases only if needed, or full dose PD, which involves daily treatment 24 hours a day. The incremental group receives up to 14 exchanges per week for continuous ambulatory PD or up to 21 for automated PD without a daytime dwell, while the full dose group receives a full 247 regimen. The study is open-label and adaptive, designed with input from patients who have experience with PD. During the trial, participants will have regular assessments including quality of life measures up to 6 months and monitoring of kidney function, adverse events, hospitalizations, and complications up to 18 months. The research team will track symptom burden, survival, cardiovascular events, and infections related to PD. The study is planned to run until September 2029, with ongoing safety and effectiveness evaluations throughout.

Age: 18Years +All GendersPhase Not Applicable
14 locations